GOOD THERAPIES ARE DIFFICULT TO DIE
A DRUG JUST RECENTLY STOPPED BY THE FDA, IS RETURNING TO THE MARKET FOR SPECIFIC INDICATIONS WITH A WORD OF CAUTION. ACCORDING TO MEDSCAPE :
"The indications are now limited to 2 groups of patients: adults with
T315I-positive chronic myeloid leukemia (chronic phase, accelerated
phase, or blast phase) or T315I-positive Philadelphia chromosome
(Ph)-positive acute lymphoblastic leukemia (ALL); and adults with
chronic-phase, accelerated-phase, or blast-phase chronic myeloid
leukemia or Ph-positive ALL for whom no other tyrosine kinase inhibitor
therapy is indicated.
The FDA has also revised the Warnings and
Precautions section of the label to describe vascular occlusion events,
including the observed arterial and venous thrombosis and occlusions
that have occurred in at least 27% of patients treated with this drug."
No comments:
Post a Comment